INOVIO PHARMACEUTICALS INC (INO) Stock Price & Overview

NASDAQ:INOUS45773H4092

Current stock price

1.58 USD
-0.07 (-4.24%)
At close:
1.58 USD
0 (0%)
After Hours:

The current stock price of INO is 1.58 USD. Today INO is down by -4.24%. In the past month the price decreased by -4.07%. In the past year, price decreased by -14.06%.

INO Key Statistics

52-Week Range1.3 - 2.9789
Current INO stock price positioned within its 52-week range.
1-Month Range1.59 - 2.03
Current INO stock price positioned within its 1-month range.
Market Cap
109.162M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.83
Dividend Yield
N/A

INO Stock Performance

Today
-4.24%
1 Week
-1.79%
1 Month
-4.07%
3 Months
-27.63%
Longer-term
6 Months -28.26%
1 Year -14.06%
2 Years -88.11%
3 Years -83.23%
5 Years -98.52%
10 Years -98.42%

INO Stock Chart

INOVIO PHARMACEUTICALS INC / INO Daily stock chart

INO Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to INO. When comparing the yearly performance of all stocks, INO is a bad performer in the overall market: 83.84% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

INO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to INO. The financial health of INO is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

INO Earnings

Next Earnings DateMay 11, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported$0.06
Revenue Reported
EPS Surprise 116.60%
Revenue Surprise %

INO Forecast & Estimates

10 analysts have analysed INO and the average price target is 8.36 USD. This implies a price increase of 429.37% is expected in the next year compared to the current price of 1.58.

For the next year, analysts expect an EPS growth of 20.26% and a revenue growth 16948.9% for INO


Analysts
Analysts80
Price Target8.36 (429.11%)
EPS Next Y20.26%
Revenue Next Year16948.9%

INO Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

INO Financial Highlights

Over the last trailing twelve months INO reported a non-GAAP Earnings per Share(EPS) of -1.83. The EPS increased by 54.14% compared to the year before.


Income Statements
Revenue(TTM)65.30K
Net Income(TTM)-84.95M
Industry RankSector Rank
PM (TTM) N/A
ROA -114.31%
ROE -352.53%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%110%
Sales Q2Q%-100%
EPS 1Y (TTM)54.14%
Revenue 1Y (TTM)-70.02%

INO Ownership

Ownership
Inst Owners48.07%
Shares69.09M
Float68.75M
Ins Owners0.48%
Short Float %16.03%
Short Ratio9.4

About INO

Company Profile

INO logo image Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 112 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Company Info

IPO: 1998-12-08

INOVIO PHARMACEUTICALS INC

660 W. Germantown Pike, Suite 110

Plymouth Meeting PENNSYLVANIA 19462 US

CEO: J. Joseph Kim

Employees: 134

INO Company Website

INO Investor Relations

Phone: 18584103134

INOVIO PHARMACEUTICALS INC / INO FAQ

Can you describe the business of INOVIO PHARMACEUTICALS INC?

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 112 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.


What is the stock price of INOVIO PHARMACEUTICALS INC today?

The current stock price of INO is 1.58 USD. The price decreased by -4.24% in the last trading session.


What is the dividend status of INOVIO PHARMACEUTICALS INC?

INO does not pay a dividend.


What is the ChartMill technical and fundamental rating of INO stock?

INO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is INO stock listed?

INO stock is listed on the Nasdaq exchange.


Can you provide the PE ratio for INO stock?

INOVIO PHARMACEUTICALS INC (INO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.83).


What is the market capitalization of INO stock?

INOVIO PHARMACEUTICALS INC (INO) has a market capitalization of 109.16M USD. This makes INO a Micro Cap stock.